Gold prices bounce off 3-week lows; demand likely longer term
NEW YORK - Goldman Sachs & Co (NYSE:GS). LLC has reported a mixed position in Mural Oncology PLC, a company specializing in cancer treatment research. According to a disclosure filed with the Irish Takeover Panel on May 2, 2025, the financial institution has both long and short interests in the company’s USD 0.01 ordinary shares.
The filing, which follows the rules of the Irish Takeover Panel Act of 1997 and Takeover Rules of 2013, indicates that as of May 1, Goldman Sachs held 90,971 shares long, representing approximately 0.52% of the company, and 183,667 shares short, which is about 1.06%. In addition to these positions, Goldman Sachs also reported derivatives in the form of a purchased swap on 1 relevant security with an expiry date of July 8, 2025, but with no exercise price listed, as it is not applicable.
The activity in shares of Mural Oncology PLC comes amid a time when investment firms closely monitor the biotechnology sector, known for its volatility and potential for high returns due to breakthroughs in medical research and drug development. The disclosure does not suggest a broader strategy but provides transparency in trading activities as required by regulatory standards.
Goldman Sachs has not disclosed any agreements, arrangements, or understandings related to the voting rights of any relevant securities under any option or derivatives referenced in the form. The disclosure was made public by contacts Papa Lette and Andrzej Szyszka, with telephone numbers provided for further inquiries.
This information is based on a press release statement and is intended to comply with disclosure requirements, presenting a factual account of Goldman Sachs’ dealings in Mural Oncology PLC without speculation on motivations or potential market impacts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.